275 related articles for article (PubMed ID: 33800801)
1. Ramatroban-Based Analogues Containing Fluorine Group as Potential
Huang LA; Huang KX; Tu J; Kandeel F; Li J
Molecules; 2021 Mar; 26(5):. PubMed ID: 33800801
[TBL] [Abstract][Full Text] [Related]
2. Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group as Potential
Yin R; Huang KX; Huang LA; Ji M; Zhao H; Li K; Gao A; Chen J; Li Z; Liu T; Shively JE; Kandeel F; Li J
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765011
[TBL] [Abstract][Full Text] [Related]
3. [
Cheung P; Amin MA; Zhang B; Lechi F; Korsgren O; Eriksson J; Odell LR; Eriksson O
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839820
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preclinical evaluation of the CRTH2 antagonist [
Eriksson J; Roy T; Sawadjoon S; Bachmann K; Sköld C; Larhed M; Weis J; Selvaraju RK; Korsgren O; Eriksson O; Odell LR
Nucl Med Biol; 2019 Apr; 71():1-10. PubMed ID: 31082767
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Visualization of β-Cells by Targeting of GPR44.
Eriksson O; Johnström P; Cselenyi Z; Jahan M; Selvaraju RK; Jensen-Waern M; Takano A; Sörhede Winzell M; Halldin C; Skrtic S; Korsgren O
Diabetes; 2018 Feb; 67(2):182-192. PubMed ID: 29208633
[TBL] [Abstract][Full Text] [Related]
6. GPR44 is a pancreatic protein restricted to the human beta cell.
Hellström-Lindahl E; Danielsson A; Ponten F; Czernichow P; Korsgren O; Johansson L; Eriksson O
Acta Diabetol; 2016 Jun; 53(3):413-21. PubMed ID: 26467464
[TBL] [Abstract][Full Text] [Related]
7. GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass.
Eriksson O
Curr Diab Rep; 2019 Jun; 19(8):49. PubMed ID: 31250117
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.
Wang Y; Lim K; Normandin M; Zhao X; Cline GW; Ding YS
Nucl Med Biol; 2012 Feb; 39(2):167-76. PubMed ID: 22033026
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the prostaglandin D
Abadpour S; Tyrberg B; Schive SW; Huldt CW; Gennemark P; Ryberg E; Rydén-Bergsten T; Smith DM; Korsgren O; Skrtic S; Scholz H; Winzell MS
Diabetologia; 2020 Jul; 63(7):1355-1367. PubMed ID: 32350565
[TBL] [Abstract][Full Text] [Related]
10. Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
Skrtic S; Tyrberg B; Broberg M; Ericsson H; Schnecke V; Kjaer M; Hompesch M; Andersson EM; Ryberg E; Aivazidis A; Wennberg Huldt C; Löfgren L; Morrow L; Parkinson J; Rydén-Bergsten T; Watkins E; Sörhede Winzell M
PLoS One; 2018; 13(12):e0208998. PubMed ID: 30557325
[TBL] [Abstract][Full Text] [Related]
11. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
12. Research Progress on
Mou T; Zhang X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28358340
[TBL] [Abstract][Full Text] [Related]
13. Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic β-cell mass.
Cline GW; Zhao X; Jakowski AB; Soeller WC; Treadway JL
Biochem Biophys Res Commun; 2011 Sep; 412(3):413-8. PubMed ID: 21820405
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.
Murakami T; Fujimoto H; Inagaki N
Front Endocrinol (Lausanne); 2021; 12():714348. PubMed ID: 34248856
[TBL] [Abstract][Full Text] [Related]
16. The development of a GPR44 targeting radioligand [
Jahan M; Johnström P; Selvaraju RK; Svedberg M; Winzell MS; Bernström J; Kingston L; Schou M; Jia Z; Skrtic S; Johansson L; Korsgren O; Farde L; Halldin C; Eriksson O
EJNMMI Res; 2018 Dec; 8(1):113. PubMed ID: 30588560
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.
Freeby MJ; Kringas P; Goland RS; Leibel RL; Maffei A; Divgi C; Ichise M; Harris PE
Mol Imaging Biol; 2016 Apr; 18(2):292-301. PubMed ID: 26370678
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
